Maduck Sean sold $1.8M of CORT

Maduck Sean (See Remarks) sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $70.21 ($70.11–$70.75, $1.76M total) across 2 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Jun 3, 2026, 11:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed sale adds new information about insider sentiment for Corcept Therapeutics.

02

Market read

The filing introduces fresh data that traders may use to adjust short‑term positions in CORT.

03

What to watch

Potential upcoming clinical data or financing events not disclosed in the filing.

Relevance 5/10Novelty 5/10Timing: post‑market today

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

Officer Maduck Sean sold 25,000 shares for $1.75M via a 10b5‑1 plan.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $1.8M sale by an officer is material for a small‑cap biotech and often leads to short‑term downside.

Market effects

May raise caution for other small‑cap biotech stocks with insider sales.

Limited to U.S. biotech sector.

Minimal global impact.

Counterpoint

The sale could be routine under a 10b5‑1 plan and not reflect negative sentiment.

Key entities

  • Corcept Therapeutics Inc.

    Biopharmaceutical company developing therapies for cortisol‑related disorders.

  • Maduck Sean

    Company officer executing a pre‑arranged 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.